Table 1 Overview of characteristics (sex, transplantation type, tumor graft, tumor cell/tissue application route, genetic background of mice, injected tumor cell/tissue type, SMI category, drug application route) of the 485 individual studies included for meta-analysis. The absolute number (n) always adds up to a total of 485. The relative number (%) usually adds up to 100%, deviations are due to rounding. The abbreviation n.m. Means ‘not mentioned’.
Characteristic | Subgroup | n (%) |
|---|---|---|
Sex | Female | 235 (48.5) |
Male | 122 (25.2) | |
Female/male | 12 (2.5) | |
n.m. | 116 (23.9) | |
Transplantation | Heterotopic | 382 (78.8) |
Orthotopic | 94 (19.4) | |
Metastatic | 9 (1.9) | |
Tumor graft | Xenograft | 363 (74.8) |
Patient-derived xenograft | 75 (15.5) | |
Syngraft | 45 (9.3) | |
Allograft | 1 (0.2) | |
n.m. | 1 (0.2) | |
Application route tumor cells/tissues | Subcutaneously (s.c.) | 380 (78.4) |
Intrapancreatic (i.panc.)* | 94 (19.4) | |
Intrasplenic (i.splen.) | 5 (1.0) | |
Intraperitoneally (i.p.) | 3 (0.6) | |
Peripancreatic (peri.panc.) | 2 (0.4) | |
Intravenously (i.v.) | 1 (0.2) | |
Genetic background | Foxn1nu | 300 (61.9) |
Prkdcscid | 68 (14.0) | |
Prkdcscid, Il2rgtm1WjI | 56 (11.5) | |
Wild type (wt) | 44 (9.1) | |
Prkdcscid, Lystbg | 3 (0.6) | |
Prkdcem26Cd52Il2rgem26Cd22 | 3 (0.6) | |
Ido1tm1Alm | 2 (0.4) | |
Pde6brd1 | 2 (0.4) | |
PNP | 2 (0.4) | |
Rag2tm1FwaII2rgtm1Rsky | 2 (0.4) | |
n.m. | 3 (0.6) | |
Tumor cell/tissue type | Patient-derived | 75 (15.5) |
MiaPaCa-2 | 68 (14.0) | |
PANC-1 | 63 (13.0) | |
Panc-02 | 29 (6.0) | |
AsPC-1 | 27 (5.6) | |
BxPC-3 | 23 (4.7) | |
L3.6pl | 23 (4.7) | |
Capan-1 | 18 (3.7) | |
HPAF-2 | 13 (2.7) | |
SW-1990 | 13 (2.7) | |
others** | 132 (27.2) | |
n.m. | 1 (0.2) | |
Small molecule inhibitor (SMI) category | Selective non-kinase SMI | 234 (48.2) |
Selective intracellular kinase SMI | 161 (33.2) | |
Selective receptor-related kinase SMI | 53 (10.9) | |
Multikinase SMI | 21 (4.3) | |
Others*** | 16 (3.3) | |
Application route drug | i.p. | 231 (47.6) |
Per orally (p.o.) | 218 (44.9) | |
i.v. | 9 (1.9) | |
s.c. | 4 (0.8) | |
Retroorbitally (r.o.) | 2 (0.4) | |
Intratumorally (i.t.) | 1 (0.2) | |
n.m. | 20 (4.1) |
